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SELECTING INITIAL REGIMENS
MR. FROST (MODERATOR): I want to ask
Dr. Saag, the question that I think is probably
one of the most frequently asked. What do you
start treatment with? Suppose a new patient,
with no retroviral history, comes to you with a
CD4 count between 400 and 500 and a viral
load of 10,000 to 15,000 copies.
DR. SAAG: There is more to consider in ini-
tial therapies than just retroviral load and CD4
count. It is also about who are they as a per-
son, how motivated are they, and are they
ready to start therapy?
MR. FROST (MODERATOR): Let's say, as a
patient, I am ready to start. I am ready to go.
DR. SAAG: Alright. Then in talking to you,
I would find out whether you want to be hy-
peraggressive or whether you want to be more
conservative in treatment approach.
MR. FROST (MODERATOR): "Gosh, I do
now know, Doc. You tell me."
DR. SAAG: In that case, with a CD4 count of
400 and a viral load of 15,000,1 would person-
ally recommend that you take d4T and ddl to
start—with the notion that we are not going to
be reducing too many options; we have a lot of
treatment possibilities to go. I think it is very
likely we will get you to an undetectable viral
load, and you can stay there for 5 years.
What is bothersome to me is a self-flagella-
tion that many of us are engaged in who have
been in this for 10 years or longer, such as, "Oh,
we really blew it. We used AZT monotherapy,
and we used ddl monotherapy." Well, that is
what we had at the time. And those drugs can-
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not carry a person through an entire decade.
But I personally would give that regimen to
keep options open. In my experience, it works
80% to 90% of the time for at least 3 to 5 years.
DR. CURRIER: I think I would also want to
involve the patient in the process of what ther-
apies we are going to begin with; that is, we
are going to make that decision together. And
I would try to give the patient as much infor-
mation as possible about the short-term activ-
ity of our choice and the probability of reduc-
ing the viral load down to a level where we
think it would stay. I would tell you that if we
treated you with AZT, ddl and, nevirapine, in
a year, there is about a 50% to 60% chance that
your viral load would make it to an undetect-
ble level, and that if it did, it may stay there for
a long time.
We would have to guess about the efficacy
of ddl, d4T, and nevirapine. There are no data
on that published in a study. I would tell you
that with the protease inhibitor combination
regimen, we probably have a better chance of
achieving an undetectable viral level. But I
could not tell you how long you would remain
there, or what we would do that would be suc-
cessful afterward.
I think with the CD4 in the range that you
mention and a viral load of 10 to 15,000—an
area where I would still feel comfortable rec-
ommending a nonprotease regimen, although
I would not use 3TC—I would make a strong
argument for nevirapine with AZT and ddl.
But I also say that there are very good data to
support that you may have a long term effect
with a protease inhibitor.
MR. FROST (MODERATOR): Why are you
holding back using 3TC?
DR. CURRIER: I think that the possibility of
failure, that is, if I just went with the
AZT-3TC-nevirapine and you develop resis-
tance to that regimen, it may make the other
proteases less active in the future. Holding back
the 3TC may provide the long-term durability
we have seen in the Merck 035 and other stud-
ies. So I would save 3TC for a protease con-
taining regimen.
DR. COHEN: What is nice about this patient
is that he is likely to respond to every single
regimen we have talked about and then some.
I personally think that it is possible to use ei-
ther all proteases first or all nucleosides first,
and successfully switch to the other if needed,
because of the lack of cross-resistance. We have
done some work with hydroxyurea, which
seems to improve the percentage suppression
with ddl-based regimens, is relatively easy to
use, and is well tolerated. At least in patients
whose CD4s were above 300, we saw increases
in CD4 counts in our study.
MR. FROST (MODERATOR): Dr. Merrick,
what are your thoughts concerning this hypo-
thetical patient?
DR. MERRICK: Rather than just starting
something at the first visit, I want to mainly
gauge the level of commitment that you, as the
patient, have.
MR. FROST (MODERATOR): I am ready to
start treatment.
DR. MERRICK: And what about your level
of understanding of toxicities?
MR. FROST (MODERATOR): I am clueless.
DR. MERRICK: Note, that is the first time he
(Mr. Frost) has ever said that. The patient needs
to understand, especially early on, the level of
toxicities of all the drugs, including a d4T-ddI
regimen, which is generally well tolerated. But
my own thinking is that durability really is the
key. What I say to patients is that I would like
to start a regimen that we are never going to
have to change.
If your definition of success is viral eradica-
tion, I think that all regimens are perhaps
doomed to failure because I think eradication
has proven to be elusive. But if we lower the
bar just a little bit and just say that we want to
start a regimen that will be durable for the fore-
seeable future, in terms of years, then I would
favor starting with a triple-therapy regimen, in-
cluding a protease inhibitor. Again, one has to
factor in adherence. And that involves a lot of
time talking to a patient even before you think
about starting a regimen. But, of course, in this
case it is not an emergency setting.
MR. FROST (MODERATOR): Assuming
those things are equal, I understand you to be
saying that a protease is something you are
leaning toward more in the initial regimen.
Yes?
Ms. Leonard, I am going to change the ques-
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tion for you because I am hoping you can give
us an idea of the clients that you counsel in
Houston and about the education you provide
for them. What types of regimens are clients
talking about, and what is the AIDS Founda-
tion of Houston talking about in terms of initial
therapy for patients when they come to see you?
MS. LEONARD: I am more for starting treat-
ment, in the case we are discussing, with a dual
therapy regimen without proteases, because
the clients that we see have trouble accessing
the protease inhibitors. I explain to them what
the ddl pill looks like, what it means when they
take it, that is, not eating before and not eating
after. You are talking about people, if they are
employed or if they are not employed, and how
that is going to affect their life-style. It is a very
nasty pill to take, and they need to know that
before they go to the pharmacy to pick up this
huge horse pill. All of this needs to be ex-
plained along with the question, "Are you
ready to commit?" They may be ready to com-
mit, and so they take their prescription with
their life-style—and everything is a little bit
harder. But I am definitely for starting off in
this particular case with dual therapy.
DR. DOBKIN: I agree with most of what has
been said. Let me just add another point. I think
an option that has not really been mentioned is
the option of waiting. I think it is clear to most
of us that eradication or cure is in the distant
future. But much better regimens are around
the corner. I think we have to remember that
the possibility of effective treatment may not
always occur simultaneously with a tolerable
and easily accessible treatment.
Those of us who are old enough to remem-
ber antihypertensive therapy 25 years ago,
knew that you could control hypertension. But
most patients could not tolerate the regimen;
therefore, most patients were not in control of
their blood pressure. I think the possibility, in
the case you present, of waiting—not using up
any of your nucleoside options—but instead
applying careful observation, and then in 6
months or a year, when an easy twice daily reg-
imen is available or even a once daily regimen,
applying those at that time—this might be the
best way to go with a lot of patients. I have
come to increasingly feel that we are rushing
many patients into therapy. I have seen series
of patients who have exhausted all the drugs
in the armamentarium within a year due to
haphazard prescribing.
DR. EL-SADR: The issue of waiting versus
initiating has not been looked at, but it might
be a viable option for anyone, not just people
with chaotic life-styles. And what worries me
even more about these guidelines is that if you
use a regimen that is not in those guidelines, it
might appear unethical or as inadequate care.
I feel sometimes that these guidelines, although
they are well-meaning in many ways, often
close the doors of potential research. Where are
we using plain gut-sense and extrapolating
from clinical experience? I mean, I honestly do
not know.
MR. FROST (MODERATOR): I think your in-
sights are appropriate and good. And I think,
especially in reference to the guidelines, which
I want to come back to, there are some inter-
esting aspects to consider. But, hypothetically,
I am your patient, and I am telling you that I
am ready to go forward with treatment. I pur-
posefully painted a picture of a patient who is
sort of in the gray area of the guidelines, some-
one who may be on the edge. However, I am
telling you "You know, I am probably ready to
start. I think it is time. I have had enough
friends who have done very well on these pro-
teases. I think it is time for me to start." Where
do we begin?
DR. EL-SADR: You say you are ready to
start, but you also mentioned that you were
clueless, and that is often the case with patients.
They feel they are ready, but they really do not
know what they are ready for. I am perfectly
comfortable with a two-drug regimen because
I am not convinced yet that, in the long run,
based on what we know today, based on a
whole different approach to suppression ver-
sus eradication, and all of the patients dis-
cussed, that we know the best option.
DR. HOLODNIY: I believe that I am another
person that would hold back the use of pro-
tease inhibitors in a case such as this where the
patient has a high CD4 count and a relatively
low viral load. But I have another reason as to
why I would do that.
I also look at the level of virologie risk. I be-
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lieve the patient that you are asking about now
is in the minimal to moderate range of virologie
risk, that is, if we are to believe any of the prog-
nostic data. And so I believe there is a poten-
tial argument for waiting, given the existing
CD4 count and level of immune function in that
particular patient. There is also an argument
for very aggressive therapy as well as triple or
quadruple therapy to bring the load level down
to less than 20 copies and maintain it. In a drug-
naive patient, the opportunity to do that and
sustain that level for at least 2 years or longer
is clearly there. So I think that is part of it.
Another issue is what do you come to the
table with, not only in terms of the psychoso-
cial aspect, but in terms of what other con-
comitant illnesses and toxicities already exist,
and do not include the antivirals? Do you have
a significant anemia? Do you have pancreati-
tis, hepatitis? These are common in the Veter-
ans Administration patients that I treat. Are
these issues that are going to enter into the mix?
So, those possibilities have to be factored in as
well. I do not think there is on "regimen dujour" that everybody is going to be able to take.
MR. FROST (MODERATOR): Yes, I didn't
expect that we would find one regimen from
this. I only wanted to find your regimen.
DR. HOLODNIY: I cannot tell you that.
There are people that I have started on
d4T-ddI. There are people that I have started
on AZT-3TC. There are some people that have
started on two nucleosides and an NNRTI or a
protease inhibitor, or just two protease in-
hibitors.
MR. FROST (MODERATOR): But you are
giving me some sense of what you are com-
fortable with. And it sounds like it is a two-
drug regimen that you are perfectly comfort-
able with, despite it being . . .
DR. MARK HOLODNIY: I have also been
comfortable waiting.
DR. BELLMAN: I will put a slightly differ-
ent spin on this in two ways. First, I would try
to get the patient excited about the possibility
of effective treatment. Clearly, you already
have some excitement about it because you
mentioned that friends are under treatment
and they are doing well. You do not seem to
feel you really need to know that much about
treatment in order to plunge right into it. I also
think that one consideration is that after 2 or 3
months, if I can tell you that your viral load is
undetectable, that everything is going great,
and there are no toxicities from the drugs, that
accounting is going to build your enthusiasm,
and potentially your compliance would con-
tinue.
And also, you may be started on the path of
what we are hoping is viral eradication, or at
least enough viral suppression that, at some
point, perhaps therapy could be discontinued,
and then you could be monitored, and if nec-
essary, return to therapy.
Since the drug regimens that we have now,
in relation to the amount of antiviral potency
that you require, are so good that it would be
very reasonable just to go with what is cur-
rently the "gold standard" in therapy: AZT,
3TC, and indinavir (Crixian). This would be as-
suming that you were very clear regarding the
issues about compliance at every level. I would
certainly want to monitor you very closely with
respect to that issue. I would add that the reg-
imen with saquinavir has no place in the guide-
lines, and I think it is an important question to
ask, in terms of ourselves, why that regimen is
actually in the guidelines at this particular
point.
MR. FROST (MODERATOR): Does anybody
disagree with that? Would anybody take issue
with the position regarding the guidelines that
the two nucleosides and saquinavir should not
be there, at least the old formulation?
DR. BELLMAN: More harm can be done be-
cause of protease cross-resistance and because
of what we have seen with people who have
switched from saquinavir and are unsuccessful
when they switch. As a result, I think it is bet-
ter to say, at the present time, that because of
cross-resistance, more harm can be done using
saquinavir in an undertreatment form.
MR. FROST (MODERATOR): Dr. Vaughn,
what are your thoughts in terms of a first reg-
imen?
DR. VAUGHN: For the population that I
serve in Newark, people usually come with a
laundry list of what they will and will not tol-
erate. Up until very recently, if it was AZT, for-
get it. They did not want to hear and they were
not going to take it. What I do with clients is
basically an inventory of life-style, considering
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meals, whether the patient works or whether
they do not work, how structured their life is,
and then also how compulsive they might be.
Because I think a better measure of adherence
is (1) believing that medication is going to work
and (2) compulsion. A very compulsive person
tends to take his medicine. Those of us who are
not so compulsive do not.
I would probably be a little more aggressive.
Up until the AIDS meeting in Vancouver 2
years ago, clearly about 35% of my patients re-
fused to take any medications—either never
started or stopped. And the Concord just con-
firmed what they felt. But post-Vancouver—
when Magic Johnson was on the cocktail—peo-
ple began saying, "I want whatever he is on.
Give me some of that."
Also, the assumption that if a person is
homeless or cannot read then he or she is not
informed about this disease is not true. I have
seen that in my community because we have
taken special efforts to educate the population.
We have focus groups, support groups, and
community forums on a very regular basis. A
lot of times, my patients educate me about ther-
apies. I have discussions with them, and then
I tailor them to what they can tolerate. I use a
lot more ddI-d4T now than I did in the past
because early on I had a lot of patients who had
a history of pancreatitis. Why? Because a lot of
folks like Colt 45 and all that other good stuff.
Then of course, some medications have a bet-
ter rap than others since they have seen and
been with their buddies. And so I tend to use
combinations that do not contain AZT, and also
to use Crixian in the cocktail.
We want to hopefully help patients work
with family members, the community, peer ed-
ucators, as well as patients who have been
through these decisions in a buddy system. By
the time patients leave my office, they have a
rigorous schedule that I have worked out with
them. Or perhaps it is not the initial encounter;
I have worked with people for several sessions
before I am sure that they are ready, that they
are committed to taking the medication. Then
we work out a schedule about what they are
going to do. For example, with the type of pa-
tient you suggested, if they are going to take
ddl, they are going to wake up and take this
medication first. After that, they are going to
wait and take the pills afterward. I explain the
meal they are going to eat, etc. Then I turn the
patient over to a nurse, a case manager, who
has a further discussion with them. A buddy
system is established with an experienced pa-
tient with whom they exchange telephone
numbers. The experienced person telephones
every day at different times to reinforce the
need to take the medicine and keep other com-
mitments. We will also discuss what they
might have to do to overcome some of the side
effects.
I am on call all the time as well as the nurses.
So patients and family members can call if they
have questions that they do not understand. If
we find out through these conversations that
the patient is not taking the medications, we
can intervene early instead of later. There are
frequent support group and forum discussions
which allow questions that we may not think
are really important, but they can be brought
up and answered right away.
MR. FROST (MODERATOR): It sounds to
me like there is a strong emphasis on the indi-
vidualization of therapy for that patient in your
clinic. Dr. Rubin, how would you address treat-
ment, as I described myself hypothetically as a
new patient with no retriviral history, a CD4
count between 400 and 500, and a viral load of
10,000 to 15,000?
DR. RUBIN: The way I usually handle the
situation in your case would be to try and as-
sess the motivation level and the education
level of the individual. If I feel that the person
can handle a protease inhibitor, and he or she
is ready, I would try to use triple therapy with
a protease inhibitor. I am hooked on triple ther-
apy. I know we are hearing from the panel that
double therapy at an earlier stage may actually
be the more prudent thing to do, but I am still
with the old school. I think that may results are
so good, in terms of the viral load changes in
the patients that I have treated, that I will not
change approaches unless I see some com-
pelling evidence to do so.
I use nevirapine with nucleosides as an al-
ternative regimen for patients whom I do not
feel would really be able to comply with the
protease inhibitors, in patients who are naive,
and in patients who are earlier on in the course
of their disease. My results have been equiva-
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lent to using a protease inhibitor. With patients
who are symptomatic or more advanced, I am
more aggressive about encouraging the use of
the protease inhibitor. I have found that there
has been very little difference, except in heav-
ily pretreated patients, between responses in
some of my more advanced patients and some
of my earlier patients in terms of CD4 changes.
So I tend to be very aggressive, but I do gauge
the issue of compliance, and I do try to make
that a major point of discussion as well as sub-
sequent discussions in terms of gauging how
adherent the patients have been with the regi-
mens.
GUIDELINE CONTROVERSIES
DR. PINSKY: I wonder if I could ask a ques-
tion from the point of view of your patient. Re-
garding the guidelines, if I were to come in and
say, "I am almost clueless, but I read about
treatment issues in these guidelines that were
put together by all these fabulous experts, and
they do not seem to agree with what you are
telling me. What has changed, or why do you
disagree with them? Could you explain that to
me in a language that someone who has only
taken a year of biology could understand?"
MR. FROST (MODERATOR): I think that is
a fair question. And I am going to add an ad-
ditional spin. I heard a few people on the panel
say they would use protease inhibitors aggres-
sively, and then I heard other people say they
might spare protease inhibitors. But I heard
very different reasons for why people might
spare protease inhibitors, or why they might
use dual nucleoside therapy. And I guess it is
a fair question, what has changed in terms of
these guidelines? Is it that the guidelines do not
reflect state-of-the-art treatment, or are the
guidelines, as we often say here, appealing to
the lowest common denominator? What is go-
ing on here?
DR. SAAG: Well, having participated in the
development of some of the guidelines, I willjust make a couple of statements. Number one,
let's think about who the guidelines are for.
They certainly are not for most of the people in
this audience, nor for the people on this panel.
Health-care providers that see a lot of patients
do not need the guidelines as they keep up with
what is changing. They see over 100 patients.
They do not need guidelines to tell them what
to do. The guidelines might make them feel
guilty about what they are doing, but they are
not going to tell them what to do.
For the people that only see a patient here or
there, the guidelines may be harmful because
they may encourage them to use therapies
about which they have little or no idea of what
they are doing. It would be like me treating a
lymphoma or leukemic patient. It have no busi-
ness doing that. I think if somebody only sees
a patient now and then, they should not be
treating at all and should not be using the
guidelines. Unless there is no option in the
community, which certainly is not the case in
the New York area, those people ought to be
referring to somebody who does treat patients.
So the guidelines basically are political. They
are there to help third-party payers do what
they should not be doing, in my opinion. That
is why, in my view, even though I am one of
the persons that developed the recommenda-
tions, I just recommended something that the
guidelines said is generally not recommended.
The reason I acquiesced was to say, what dif-
ference does it make? If I wanted to choose all
three agents, I do not want a third-party payer
saying, "Well, the guidelines say you are not
supposed to do that in this setting." So, I think
having them err on the side of overaggressive
therapy, in my opinion, was appropriate. That
is basically wanting to have a reality check
there.
MR. FROST (MODERATOR): Is that some-
thing you might say to a patient?
DR. SAAG: Absolutely. You bet.
MR. FROST (MODERATOR): These are po-
litical guidelines? They do not really tell me
how to
. . .
DR. SAAG: Well, I do not know if I would
go into all that much detail. To answer your
question, I would speak in biologic terms. That
is not so hard to understand. We use the terms
"a billion to ten billion viruses produced a
day." That gets people's attention, or you can
translate more figures to "485 million virions
an hour." That is a pretty heavy viral load. That
is easy to understand.
If I had to summarize, when most patients
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come in, this disease is very mysterious to
them. They do not understand how they can
feel well and be told all these bad gloom and
doom things that are going to happen to them
in the future. They do not understand why it
is not happening now, or why it is not hap-
pening tomorrow, exactly tomorrow. When I
start to explain the biology, you can often
watch the light go on. Then when I start talk-
ing about therapy, again, I make a clear dis-
tinction between clinical benefit and preven-
tion of resistance. That is how I couch the
discussion, that what we are really talking
about is the importance of viral load, that it is
a measure of how effective these therapies are
before you might get sick from the disease. I
explain that if we focus on that as our yard-
stick—as our virometer, if you will—then we
can know in advance when to switch therapy.
They need to understand this concept as a guid-
ing principle as opposed to always looking for
another in clinical trials that are waiting for
people to be on their way to the grave.
ARE ALL THERAPIES DOOMED
TO FAILURE?
MR. FROST (MODERATOR): Fair enough, I
think. You know, this very bright doctor that I
know tells me that all of these therapies are
doomed to failure. I am wondering—does the
panel agree? Because that is really bad news to
me. Are all these therapies doomed to failure?
CAL COHEN: I think what Dr. Saag said is
that we do not know if some of these regimens
we have talked about might last for as long as
this person is alive. I think what is accurate is
that it is entirely possible that some of these
regimens we have all used, and like using, may
work for the life of the patient. We certainly all
have patients who are successful beyond our
wildest dreams from 2 years ago; they went
from 42 T-cells to 442 T-cells. They are as
healthy as they want to be, have managed to
take the pills on schedule, and are doing great.
We are now 2 and 3 years into this situation. If
the first 2 and 3 years are any prediction of the
next 30, then it is possible that some of these
regimens will last for life. I think that's obvi-
ously what we're looking for.
I think what Dr. Saag says is not that in each
person the regimens are doomed to failure. It
is that in a subset of people that we give these
agents to in a population that we treat, this ap-
proach does not seem to be holding. And since
we do not yet know how to predict who is go-
ing to be the success and who is not, then it
makes us a little gun shy. If I could predict in
whom this triple therapy would be successful
for the rest of their lives, I would give it to only
them and not to other persons.
But we are still learning how to do this. If
you get gun shy, you are likely to say, "Well, I
guess I will back off with everybody." I think
the challenge for 1998 is in predicting failure,
as opposed to expecting it. In predicting it,
what are the things that allow us to say, "You
know what? This regimen is working. It will
continue to work. And all these tests will tell
me that confidently." I do not think we have
those tests yet.
I think what we need is something between
Mark Holodniy's talk on therapeutic drug
monitoring and perhaps the "Star Trek mo-
ments" in which you can just kind of go
"Whew!" and tell that the regimen is working.
MR. FROST (MODERATOR): Well, Dr. Saag,
are you saying, that all these therapies are
doomed to failure or ... ?
DR. SAAG: We should assume that they are
doomed when we think that that should be a
driving force of our thought process so that we
are not just blissfully waltzing down the "Yel-
low Brick Road," running toward Oz. We
should be thinking, "What if? Be prepared."
And hopefully they will not fail. But what if
they do?
In the case that you presented, I sort of
backed into a default mode with d4T-ddI. If
you made the viral load higher, I would have
been more aggressive and used triple-drug
therapy or even quadruple-drug therapy with
a whole different focus for that individual, even
if the CD4 count were lower. I think that it all
depends. I am just saying you should be pre-
pared for failure.
MR. FROST (MODERATOR): Yes, I hear
that. And I understand that this is an intellec-
tual process, to a certain extent, that you are us-
ing as a tool because you are thinking ahead.
How much of that process do you share with
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patients? Would you say to a patient, "This is
what I'm doing for you today, but. . ."
DR. MICHAEL SAAG: You bet. When I write
down that plan, I am talking to the patient
about it. "This is what we are going to start you
on today. This is what we want your viral load
to be in 8 to 12 weeks. This is what we are go-
ing to do if and when this regimen no longer
works. And this is likely what we are going to
go to. What do you think of that?" So that we're
on the same page together literally.
And that is critical to starting regimens be-
cause when you lay it out for patients, they may
say, "No, no, no. You know, I'd rather not do
this d4T-ddI thing. Let's move into more ag-
gressive therapy." Great! Let's do it.
By bringing the patient into the process, you
not only improve adherence, they are more en-
gaged because they're part of the team now.
MR. FROST (MODERATOR): Sure. You're
looking at these viruses in the test tube. And
you're looking at them even in patients who
have really low viral loads. Are these regimens
going to fail these patients? Are we going to
find resistance?
DR. HOLODNIY: As I alluded to in my dis-
cussion, in some patients we do, and in some
we don't. And to go one step further about ini-
tiation, I have some patients in the clinic who
are on AZT monotherapy, or they're on d4T
monotherapy. Their CD4 counts are 300, 420
with Viral loads of 1100,600, respectively. They
have been on those monotherapies for 5 years.
We have the same discussion every 4 months.
I say, "You know, this is not good. It's against
the guidelines."
And they say, "Well, but, what has
changed if anything over the last 36
months?"
And I say, "Nothing."
And they say, "Well, why should I add
anything?"
And I say, "Well, the national opinion
leaders suggest that you need to be on
more."
And they say, "I don't want to be on
more. I'm comfortable where I'm at. I'm
trending what's going on. I'm tracking it
with you. And I don't need to be any-
thing."
Now, when you fish some of those viruses
out of people, believe it or not, it is a crapshoot.
Some of them have, believe it or not, resistant
virus. Yet, they have very low viral loads, and
their T-cell counts haven't changed. Some of
them have wild-type virus, or they have mix-
tures. I have this sense of urgency that I need
to add or change agents. But if I look at the big-
ger picture over 5 years, what immunologically
or virologically has changed in that person?
The answer is, not much.
So in those particular people, I am not sure
that information helped me. It confused me
more. And I look again at what we have looked
at for years and years. And that is: What is the
T-cell doing over time? Then I add the dimen-
sion of viral load. The resistance testing did not
help me in that regard.
However, there are clearly people in
whom—and this again is not necessarily in the
drug-naive patient, but in the heavily-experi-
enced patient—some additional information
can be useful. It is really in those people that I
look at resistance issues and say, "Okay. The
genotype is this, and that allows me to go down
this pathway." Or, "The genotype is this, and
I cannot go down this pathway based, at least,
on the rules that we understand today."
RESISTANCE TESTING
DR. SAAG: Let me react to that just for a sec-
ond because I'm not sure that the genotype tells
us what direction we can and cannot go in. Let
me play devil's advocate for a minute.
DR. HOLODNIY: Okay.
DR. SAAG: We have Dr. Vicki Johnson at our
site who does resistance testing as part of the
research. Therefore, the patients receive testing
free. We have her come in and we play a game
where, when the data comes back, I'll say to
the nurse practitioner, "Okay. Give me infor-
mation, either their resistance data or their reg-
imen. And I will predict the answer." And it is
not that I am so smart. It is just that it is easy
to predict.
If the nurse gives me the resistance genotype,
I say, "Okay, that person has been on, in the
past, this, this, and this."
And they say, "Yes, you're right," or they
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say, "Tell me what they're on, and I'll predict
what resistance mutations they have."
More times than not, I am right. But it does
not change what I do because, as you have said,
there are mixtures of viruses. And more im-
portantly, it is such a static determination I
think it's not only a waste of money to get re-
sistance testing as a matter of routine practice.
I would argue that it is almost ethically wrong
because we are paying dollars out for data that
does not tell us more than what a drug history
does, to play devil's advocate. Let's spend that
money on the drug.
Let me just point out, I think just to be fair,
since we are all talking about a radical shift in
what has been the standard opinion, there are
at least two arguments that are voiced to
counter a lot of what is being said here.
One is what is the cost to the immune sys-
tem of controlling low levels of virus, and is
there some irreversible damage to having 5000
copies that we are not worried about?
And the second is cross-resistance, which we
have certainly downplayed. But the question is,
would d4T-ddI resistance make it less likely to
have subsequent success. Your first chance is
your best chance because cross-resistance when
a codon 151 mutation shows up might mean
that, in fact, this person is going to be in a lot of
trouble. Had only we treated more aggressively,
maybe the regimen would have lasted for life?
So there is a kind of a two-sided coin. We
may not have a vocal enough representative of
that. But there are some very powerful argu-
ments to the alternative strategy.
CASE ONE
DR. HOLODNIY: This patient had a pro-
found response and rebounded very quickly.
And that is what we would expect on
saquinavir monotherapy. What we see is the
rapid development of a vel-90-mutation in the
protease gene, which is indicative of resistance
to saquinavir. You can see that that genotype
comes up essentially on par with the virologie
rebound in this patient.
In this particular patient, if he were in the
clinic, and you had one test to choose to mon-
itor his therapy, you would say, "Well, viral
load is what I need." He rebounded. Then I
would probably say, "That was due to virologie
failure—the development of resistance." I do
not need to spend $600 to convince me that I
need to do something else, and he is probably
resistant to this drug. So, in this particular kind
of patient, genotype testing is not useful infor-
mation.
It becomes a little muddier when you start
getting more types of resistance mutations.
And so in this particular patient, what you have
is, again, monotherapy with a protease in-
hibitor.
There are other concomitant mutations that
appear to be developing. We key in on the 63
mutation, which is a compensatory mutation.
Some of these compensatory mutations such as
the 63 and the 71 predate the development of
the mutations that actually confer resistance to
the drug.
So the 63 mutation pops up very quickly,
which is then followed by an 82, and subse-
quently by an 84. The 82 is the pivotal muta-
tion for ritonavir, 84 being a secondary muta-
tion.
DR. SAAG: Yes, but look at a time frame
there in his case. For you to pick that up in prac-
tice, you would have to be doing genotyping
every 30 days, or 15 days. I mean, is that rea-
sonable? I mean, what have you gained by that?
DR. HOLODNIY: Well, right now it is not
reasonable, because we do not know what the
rules of engagement are. But if we get better at
this, and we actually have a good data base and
a knowledge base as to what these mutations
mean, we can soon know if a 63, in fact, has
predictive value.
DR. SAAG: Or does it come up in every pa-
tient?
. . .
DR. HOLODNIY: We do not know that.
DR. SAAG: That is my point.
DR. HOLODNIY: Right. And I agree with
you. We are beginning to get that information
out as we look at these patients and begin to
understand some of the rules.
CASE TWO
DR. HOLODNIY: The next patient is a pa-
tient in my clinic. He has been infected since
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about 1986, heavily nucleoside pretreated, and
was on saquinavir when it first came out. Then
the regimen was switched to indinavir. He was
genotyped at this particular point after having
been on two protease inhibitors. And surpris-
ing to me, he had failed on an indinavir regi-
men. But you can see what his viral loads are.
They are in the 200,000 to 300,000 range. The
only note of significance in the protease gene
was a vel-90-mutation, which he had devel-
oped from saquinavir therapy. He did not have
any of the other mutations that are associated
with indinavir. This is a very compliant patient.
Also, at this point in time, he did not have the
pivotal mutation that we think goes along with
nelfinavir resistance.
So this patient has his whole regimen
changed. This time we went by the guidelines.
And low and behold, he had no response to a
nelfinavir-containing regimen. The question is
why. What we have found in this patient, and
at least four or five other patients, and some
data that Agauron actually has, is that in pa-
tients—in the absence of a D-30 mutation, but
in the presence of a v-90 mutation, they will not
respond to nelfinavir.
So, there again we begin to describe new
rules of what we can use next in terms of a sal-
vage regimen. And this was very surprising to
me, but not unexpected based on where that
mutation is in the active site, and the possibil-
ity that the drug will not work because of that
mutation.
I have five patients in the same boat—I know
if I have this mutation information, with nelfi-
navir, that the possibility of diarrhea and the
possibility of other drug interactions are real
and they are not events I want to introduce into
the regimen. So in this particular case, this in-
formation was useful for subsequent patients,
but not for him, unfortunately.
CASE THREE
DR. HOLODNIY: This is a patient being
treated at San Francisco General who had been
heavily pretreated on the nucleosides, and was
on ritonavir. In addition to that, he had evi-
dence of the 82 mutation known to confer ri-
tonavir resistance.
Interestingly, in this patient, when they
changed to saquinavir, what they saw was a
nice reduction in viral load. But we also saw
the disappearance of the 82-A mutation, which
was unexpected in this particular patient. In
fact, we saw the characteristic virologie re-
bound on a saquinavir regimen and with it the
development of a v-90 mutation.
Now, a decision needs to be made about
what to do. He has viral load in the 100,000 or
so range. Where can you go? And it was inter-
esting. Again, if you scan these particular pro-
tease codons here—wild type at 30—he does
not have any of the mutations that we would
see with indinavir. And surprisingly, the 82
had disappeared, and we were back to the va-
line wild type.
Because there were no pivotal mutations
known for indinavir in this particular patient,
but only the saquinavir v-90 mutation, the de-
cision was made to change him to an indinavir-
related regimen. In this patient, we had a nice
virologie response that was sustained.
DR. SAAG: If you put a block on the bottom
part of the slide, you have somebody who has
already failed ritonavir and failed saquinavir.
You do not have many options left. You are go-
ing to be doing indinavir no matter what any-
way, just on the fly. And the 3TC makes no
sense because the 184 mutation is still there.
Clinically, without the other data, I would have
moved to nelfinavir and indinavir-d4T at a
minimum, with or without a non-nucleoside.
DR. HOLODNIY: Right.
DR. SAAG: I don't know for sure, but I
would bet you would get a similar response.
DR. HOLODNIY: But haven't your national
opinion makers and your guidelines suggested
that if you are ritonavir experienced, you can-
not move to indinavir?
DR. SAAG: I would not read it that way. The
bottom line is those guidelines are not meant
for people that are taking care of patients every
day. They are meant for the third-party payers.
DR. HOLODNIY: Right. So you would have
felt comfortable, after having failed on riton-
avir, to go back to indinavir?
DR. SAAG; I would have had no other
choice. I would have been there just because it
had not been used yet. It is sort of what Dr. Co-
hen said earlier: "Look at the list, see what you
have not used, and use it."
DR. HOLODNIY: Even though you know
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what the rules of engagement are in the rela-
tionship between those . . .
DR. SAAG: The rules of engagements are
based on about as much data as we have rules
of engagement based on genotype.
DR. HOLODNIY: I agree.
DR. SAAG: You fly by the seat of your pants
like we have always done. And you use what
you've got.
DR. HOLODNIY: Right.
DR. CURRIER: I think the other point is that
this approach may have worked for this pa-
tient, but we are not sure why. I think you have
to be very careful about drawing conclusions
from single patients using genotype informa-
tion because we are not always sure that we
know all about the things we should be look-
ing at. It may be some important secondary
mutation that the person did not have, which
was they were able to do okay, rather than
something that they did have.
DR. HOLODNIY: Believe me. I am not a
salesman to sell the test. I am trying to make
some sense out of whether the test has utility.
But what you said is exactly true. I mean, we
are individualizing therapy. We have to indi-
vidualize where this test may be useful as well.
And it is not a test for all patients.
INDIVIDUALIZING
RESISTANCE TESTING
MR. FROST (MODERATOR): This brings up
a question then. How do we individualize this?
I'm wondering how many people are using it,
and when do you use it? Who do you apply
this assay to? You are not a salesman, but there
are salesman out there pushing this test. And
there are a lot of people in the community who
are saying, "I need to have this test done. I need
to know what I am resistant to so I can tell what
I should take?" So when do you get it done?
Who do you use it on? Who's the patient?
DR. COHEN: I would like to add something
to that slide. I do not think that the response
that is actually shown necessarily represents a
significant clinical response because the viral
load is still plateauing at a detectable level. It
is possible it could go down further. But given
the degree of resistance that has already oc-
curred, and of course, almost certain 3TC re-
sistance, etc., I would guess that that regimen
will fail very quickly and independent of the
issue of whether or not the genotypic test was
helpful in terms of choosing it.
I think that, regarding salvage therapies, that
genotypic testing is fairly limited in its utility.
Maybe the only way that we can go is just based
upon the data that accumulate with respect to
what salvage regimens work, and how many
of what percentage of people with respect to
previous regimens they have been applied to.
And that's a regimen that I just think has al-
most no chance.
MR. FROST (MODERATOR): Dr. El-Sadr?
DR. EL-SADR: Yes, I think this is a good ex-
ample of how technology sometimes runs
amok—ahead of our ability to use the technol-
ogy. I am deluged with all the companies that
are doing these tests. Medicaid in New York
State is apparently covering these assays at this
point without us being able to interpret the re-
sults.
And the key issue is what is the clinical sig-
nificance? I am concerned to because I also
wear a research hat. When you try to do a study
how to determine the clinical significance of all
these assays, with providers and patients who
already think they know the clinical signifi-
cance, it becomes impossible to do some of
these studies. So we are stuck because they
think the technology is going ahead of the
knowledge in interpreting the results of these
assays.
DR. COHEN: My personal response, by the
way, when these salesmen come in is, "Show
me the study that tells me that this test actu-
ally will help over and above my own guess-
work, because I would be happy to order it
once you show me that study." And since none
of them have such a study, then all I can tell
them is that I am still waiting. I also say if you
would like to do some research to prove your
test is worth the dollars, I would be happy to
help you. But that is your money. That is not
my money. Then you will get my money be-
cause you have proven your point.
DR. SAAG: But it is your money. I'll be very
controversial. I come from a state where we
have 100-plus people on a waiting list who can-
not get protease inhibitors because our ADAP
funding is exhausted. To receive Medicaid in
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Alabama, you must earn less than $500 a month
and have a net worth of less than $2,000.
So to hear about a state that is paying out of
their Medicaid budget for testing, when we
cannot get access to drugs is disturbing. It is
our money. And it is criminal in my opinion.
DR. HOLODNIY: I do not know if I would
say "criminal." But I totally agree that it is ir-
responsible. And I don't think the studies are
there.
DR. SAAG: I mean, legally criminal.
DR. COHEN: As you mentioned yourself,
they are very reticent to even give us good data
about the reproducibility of the test. And wejust have absolutely no hard data that these
tests are useful. I wasn't aware that Medicaid
is paying for them. I am shocked. Someone got
a genotype recently on a newly diagnosed pa-
tient they had, but have not started on therapy.
Really what it served to do was make them
more scared, more confused. "You know, we
may have some d4T resistance. Maybe a 41 and
some AZT resistance—maybe."
So now he is saying, "Well, what I'd really
like to take are these three drugs because that
fits into my life, and I want to take something
with food, and this is what I really want to take.
But now I'm scared to do that. Maybe I should
take this stuff that I don't think I can tolerate,
that I don't think I can comply with."
And again, if it turns out that that data, in
fact, suggest that he should stay away from
those drugs, then it could be useful. But we do
not have the proof.
MR. FROST (MODERATOR): How many of
your clients are talking about genotype and
phenotype these days? How important is re-
sistance in the Houston community?
MS. LEONARD: When it first came out, with
the novelty of it, we had people asking about
it and so forth. But it has gone away. It is too
overwhelming for people with everything else
and just too confusing.
MR. FROST (MODERATOR): Did you think
the lack of data around utility has contributed
to that?
MS. LEONARD: We are talking about
whether these drug regimens over the years
will fail or whether they will extend some-
body's lifetime. But I would like to bring up the
fact that the toxicities over a lifetime, such as
adult-onset diabetes and so forth, and some of
the side effects of these drugs, are just as im-
portant an issue as whether they can sustain vi-
rologie response.
MR. FROST (MODERATOR): I think that is
fair.
MS. PINSKY: Yes, I had a comment and two
questions. I am somewhat distressed to hear
the rejection of the idea of guidelines, not those
specific guidelines, perhaps, but guidelines in
general because I think then you always have
a patient in a position of having to trust the
doctor's judgment, whatever individual doctor
he or she is seeing. I think that is a problem. I
would be interested in knowing whether the
other people on the panel who suggested us-
ing two-drug combination therapy also think
that the recommendations were written the
way they were only for sort of economic /po-
litical reasons. And if not, why they disagreed
with the guidelines. Also, if they start people
at a higher level of viral load and a lower level
of CD4 cells, they still must have a number in
mind. What are those numbers?
MR. FROST (MODERATOR): Dr. Dobkin,
why don't you tackle that?
DR. DOBKIN: Let me just point something
out beforehand. There were two documents
produced at the same time. The other one,
which is not called guidelines, I believe is called
"Principles of Antiretroviral Therapy." I think
this document is extremely useful because it
summarizes a great deal of data in a concise
form, most of which is not in textbooks, and a
lot of which is not even in journal articles.
I have found it to be an extremely useful doc-
ument for education. A lot of our house staff,
2 or 3 years out of medical school, do not know
about any of the issues that we are talking
about this morning. So I think there are guide-
lines and there are guidelines.
As far as the specific question is concerned,
I think a knowledgeable user, and this should
include a patient, looking at those guidelines
has to realize what the limitations are of clini-
cal trials, what a consensus means, and that it
is not etched in stone by any means—that this
is not a cookbook or a prescription that can be
applied in robotlike fashion.
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MR. FROST (MODERATOR): Dr. El-Sadr?
DR. EL-SADR: Yes, I actually support the
guidelines, having been involved in develop-
ing some of them. Usually in guidelines, how-
ever, you have at least an acknowledgement of
the level of certainty for each of the recom-
mendations. And I think what worries me
about these guidelines is that they are written
without any indication of what each statement
is based on. Is it simply expert opinion or is it
based on a clinical trial? Is it based on obser-
vational studies? So, the reader really has no
way of judging the strength of the evidence.
DR. COHEN: What also upsets me about
the guidelines is that they are a bit glib about
plan B. In other words, what they say is give
plan A.
DR. SAAG: Let me sort of qualify my earlier
comments. Is there a need for guidelines? Yes.
Are they helpful? Yes. But I think we have to
accept them for what they are. They are not dic-
tums. They are guidelines. They are sort of road
maps that you can follow, or you might not.
And all of them say individualization of ther-
apy.
What I was trying to say is that when we
think about the impact of the guidelines on dif-
ferent target audiences, how they play is very
different. So when you pitch guidelines to ex-
perienced "treaters," they are taken in the right
spirit, I think. And there is a lot of comfort
among experienced treaters to do what they
need to do without feeling overly guilty.
And for the people that are inexperienced
treaters, then the algorithm situation kicks in,
and people start following it blindly, and get-
ting patients into trouble because they do not
have the depth of understanding of the princi-
ples that Dr. Dobkin was referring to.
So, I think they are helpful. I am not saying
that they do not have a place. I am just saying
that we should not put so much stock in them
as if they are dictums. They are simply what
they are—guidelines.
DR. HOLODNIY: I just want to give an anec-
dote in an entirely different area, which just
happened to me. We were called to see a pa-
tient with infective endocarditis. The house
staff working up the patient looked at the
guidelines published in JAMA earlier this year
regarding what constitutes infective endo-
carditis, and there are major and there are mi-
nor criteria. They looked at that, and said, "This
patient doesn't fit the criteria of infective en-
docarditis." So they inadequately treated the
patient in terms of duration.
The follow-up to the story is the patient, in
fact, had infective endocarditis, and had to go
for valve replacement. It was confirmed on
histopathologic grounds when the valve was
taken out.
So, again, the subtleties of it are important.
And guidelines are useful as a framework. But
there is a danger in adhering to those guide-
lines for whatever it is, if it is prostatic hyper-
trophy or it is infective endocarditis or what-
ever; if you take those guidelines too
concretely, then patients will get into trouble.
